Solutions - Page 2

Lupin Pharmaceuticals, the U.S. unit of India’s Lupin Limited, issued a voluntary recall of more than 2.5 million bottles of prednisolone acetate ophthalmic suspension after an undisclosed contaminant was discovered.

When launching a drug as big as semaglutide, even as a generic, expectations are immense. Any fumble by a manufacturer can take a toll.

Catalent is shedding one of its U.K. manufacturing facilities as it inks a separate partnership deal to advance a new gene therapy, expanding in certain areas while scaling back in others.

While not on the same scale of some of Big Pharma’s major carveouts in recent years, the deal follows a noticeable pattern in which diversified drugmakers have simplified their structures to focus

Amgen has issued a voluntary recall for nearly 1 million bottles of the heart medication Corlanor (ivabradine) due to possible contamination.

Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is expanding its capacity to manufacture antibody-drug conjugates—and that it has increased the

On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is going down the path of M&A.

Eli Lilly, Regeneron and Fujifilm are among the seven companies that have been selected to participate in the FDA’s PreCheck Pilot Program, designed to strengthen drug manufacturing and supply chain resilience in

Unicycive is optimistic the third-party manufacturing facility can meet FDA standards to support an approval, CEO Shalabh Gupta, M.D., said in a statement.

Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA.